leisure time -WSS

leisure time

author：fashion 2025-09-06 02:05:52 - browse：4297

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Readout Newsletter: Biotech news, including Moderna's Covid vaccine

WSS

The lessons of Aduhelm, an Alzheimer's drug that was not to be

FDA authorizes Novavax’s updated Covid

Some dementia cases could be undiagnosed liver disease

What we need to know about Arena Bioworks

Sana to lay off nearly a third of staff, de

Chan Zuckerberg Biohub Chicago to focus on inflammation

focus

leisure time

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What to expect at HLTH 2023, the health care industry conference

Dobbs anniversary: the lost opportunity of abortion as health care

Cognito secures funding to test medical device for Alzheimer's

Affirmative action in medical school literally saved lives

Why Charlie Gard's case is so disturbing to Americans

How one medical school became remarkably diverse

Some dementia cases could be undiagnosed liver disease

Duchenne breakthrough therapy leaves behind pioneering families

A $475,000 price tag for a new cancer drug: crazy or meh?

knowledge

The future of health care in the House

What we need to know about Arena Bioworks

A $475,000 price tag for a new cancer drug: crazy or meh?

3 questions for the future of Biden's cancer moonshot

Liquid biopsy for lung cancer is launched by Delfi

What to expect at HLTH 2023, the health care industry conference

hotspot

leisure time

focus

hotspot